Canada Markets closed

Protagenic Therapeutics, Inc. (PTIX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.9500-0.0100 (-0.51%)
At close: 4:00PM EDT
1.9600 +0.01 (+0.51%)
After hours: 05:29PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close1.9600
Open2.0000
Bid1.9500 x 800
Ask1.9600 x 800
Day's Range1.9300 - 2.0000
52 Week Range1.5500 - 4.8900
Volume83,188
Avg. Volume442,956
Market Cap28.555M
Beta (5Y Monthly)-0.62
PE Ratio (TTM)N/A
EPS (TTM)-0.3130
Earnings DateJun. 18, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Protagenic Therapeutics to Host Virtual Science Review Wednesday, September 8th at 10 AM ET

    Scientific rationale and evidence for PT00114 in the treatment of Depression, Anxiety, PTSD and Addiction to be discussed NEW YORK, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders, today announced that it will host a Scientific review of its programs designed for the treatment of patients with Depression, PTSD, Anxiety and Addiction. The review will take place o

  • GlobeNewswire

    Protagenic Therapeutics Announces Second Quarter 2021 Results and Provides Business Update

    NEW YORK, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders, today announced results for the second quarter ended June 30, 2021. Recent Highlights Closed a $13.2 million public offeringUp listed to the Nasdaq Capital MarketHosted a key opinion leader (KOL) webinar focused on PT00114 for the regulation of stress in patients with Depression, PTSD, Anxiety and Addict

  • GlobeNewswire

    Protagenic Therapeutics Updates Timeline for Commencement of Patient Enrollment for PT00114 Clinical Trial

    NEW YORK, July 23, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders, today announced that upon reviewing its investigational new drug (IND) application filed on June 29th, the U.S. Food and Drug Administration (FDA) has requested that Protagenic provide clinical sites with ready-to-inject clinical vials rather than providing site pharmacies with drug substance to be formu